ADAR1 Capital Management LLC purchased a new stake in Geron Corporation (NASDAQ: GERN) in the undefi

FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercia

Genron Corp. reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1

Geron (NASDAQ: GERN - Get Free Report) and Shattuck Labs (NASDAQ: STTK - Get Free Report) are both s

Geron Corporation (GERN) Q2 2026 Earnings Call Transcript

Geron (GERN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate o

Geron NASDAQ: GERN reported second-quarter net revenue of $57.5 million, up 17% from a year earlier

Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% c

Geron (NASDAQ: GERN - Get Free Report) is projected to issue its Q2 2026 results before the market o

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercia

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercia

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company

FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercia

Mr. Rath brings senior leadership experience in business development across a range of biopharmaceut

Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutiv

FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercia

Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra

Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy sel

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercia

Geron has secured FDA approval for RYTELO in low- to intermediate-1 risk MDS, marking a pivotal mile

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and effica

Geron (NASDAQ:GERN) reported quarterly losses of $(0.01) per share which beat the analyst consensus

U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear

Geron (NASDAQ:GERN) reported quarterly losses of $(0.05) per share which missed the analyst consensu

On December 16, 2025, Geron Corporation (the "Company") began implementation of a strategic

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cyt

2025 Financial GuidanceFor fiscal year 2025, the Company expects total operating expenses will be be

New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores rela

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial

Geron (NASDAQ:GERN) reported quarterly losses of $(0.02) per share which beat the analyst consensus

Goldman Sachs analyst Corinne Jenkins reinstates Geron (NASDAQ:GERN) with a Sell and announces $1

Goldman Sachs analyst Corinne Jenkins initiates coverage on Geron (NASDAQ:GERN) with a Sell ratin

New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with l

Geron (NASDAQ:GERN) reported quarterly losses of $(0.03) per share which beat the analyst consensus